Status:
COMPLETED
Study Evaluating Safety and Efficacy of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal Women
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Endometrial Hyperplasia
Osteoporosis
Eligibility:
FEMALE
40-75 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine whether bazedoxifene/conjugated estrogens combinations are effective for the prevention of endometrial hyperplasia and for the prevention of osteoporosis in p...
Eligibility Criteria
Inclusion
- Generally healthy, postmenopausal women aged 40 - 75 years inclusive
- Intact uterus
- Last natural menstrual cycle (without exogenous hormone therapy) completed at least 12 consecutive months before screening
Exclusion
- A history or active presence of thrombophlebitis, thrombosis or thromboembolic disorders
- A history or active presence of cerebrovascular accident, stroke, or transient ischemic attack
- A history or active presence of malignancy, or treatment for malignancy, within the previous 10 years
- Additional criteria applies.
Key Trial Info
Start Date :
April 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2006
Estimated Enrollment :
3544 Patients enrolled
Trial Details
Trial ID
NCT00675688
Start Date
April 1 2002
End Date
January 1 2006
Last Update
May 12 2008
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.